Trials / Completed
CompletedNCT01245530
An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia
Probable Alzheimer Type Dementia Compare INM-176 1200~1600mg/Day With Donepezil 5~10mg/Day of Safety and Efficacy to Randomization, Multicenter, Double-blind, Double-dummy, Parallel Phase III Clinical Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 280 (actual)
- Sponsor
- Whanin Pharmaceutical Company · Industry
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of two fixed dose (1200mg/day, 1600mg/day) of INM-176 (a drug of treating dementia) comparing with donepezil for treatment for patients with Alzheimer type dementia.
Detailed description
Probable Alzheimer type dementia compare INM-176 1200\~1600mg/day with Donepezil 5\~10mg/day of safety and efficacy to randomization, multicenter, double-blind, double-dummy, parallel Phase III clinical study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aricept | Aricept Comparator Intervention: Drug: Aricept 5\~10 mg orally every day for 24weeks |
| DRUG | INM-176 | INM-176: Experimental Intervention: Drug:INM-176 600\~1200 mg orally every day for 24weeks |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2011-02-01
- Completion
- 2011-03-01
- First posted
- 2010-11-22
- Last updated
- 2011-06-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01245530. Inclusion in this directory is not an endorsement.